source
- Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamParabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...Endpoints · 1mo ago↗ source
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.BioPharma Dive · 1mo ago↗ source
- Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib induce…